Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN2 | Q96KS0 | 3/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.35 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.35 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.35 |
| ▸ | PDK3 | Q15120 | 2/20 | 0.35 |
| ▸ | PDK4 | Q16654 | 2/20 | 0.35 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 2/20 | 0.35 |
| ▸ | RORC | P51449 | 3/20 | 0.34 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.34 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.34 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.34 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.34 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.33 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12209862 | 0.95 | EGLN2 (0.43) | EGLN2KCNH2SCN10APDK1PDK2 | |
| SCHEMBL1025849 | 0.87 | BRD9 (0.36) | PTPN11NAMPTPTGDR2BRD9PDGFRB | |
| SCHEMBL1022925 | 0.85 | GAA (0.40) | — | |
| SCHEMBL1022924 | 0.85 | GAA (0.40) | — | |
| SCHEMBL2515901 | 0.84 | EGLN2 (0.35) | EGLN2FFAR1PDK1PDK2PDK3 | |
| SCHEMBL13622747 | 0.82 | NAMPT (0.39) | EGLN2NAMPTPTGDR2BRD9PDGFRB | |
| SCHEMBL1476179 | 0.80 | PDK1 (0.46) | EGLN2PDK1PDK2PDK3PDK4 | |
| SCHEMBL13622742 | 0.79 | PKM (0.41) | NAMPTSIRT2 | |
| SCHEMBL2520961 | 0.79 | EGLN2 (0.38) | EGLN2PDK1PDK2PDK3PDK4 | |
| SCHEMBL21605007 | 0.78 | EGLN2 (0.47) | EGLN2KCNH2SCN10APDK1PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8765727-B2 | Macrocyclic compounds and their use as kinase inhibitors | INCYTE CORPORATION (US) | 2014-07-01 | — | — | US | disclosed |
| US-20110251215-A9 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2011-10-13 | — | — | US | disclosed |
| US-20100190804-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2010-07-29 | — | — | US | disclosed |
| WO-2010085597-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2010-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251215-A9 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | JAK2, JAK1, ALK | EGLN2 2197/4885FFAR1 1611/4885KCNH2 644/4885 |
| US-20100190804-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | JAK2, JAK1, ALK | EGLN2 2197/4885FFAR1 1611/4885KCNH2 644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.